Combative patients given prehospital midazolam as a chemical restraint: Adverse events and efficacy in the Emergency Department

L. Leggatt, M. Leschyna, P. Bradford, P. Morasutti, K. Van Aarsen, M. Davis

Southwest Ontario Regional Base Hospital Program, London Health Sciences Centre, London, Canada
Division of Emergency Medicine, Department of Medicine, The University of Western Ontario, London, Canada

Introduction

• Paramedics are often required to manage violent or combative patients wherein chemical sedation may be required to assess and treat patients safely
• There are currently a number of pharmacologic agents used in the pre-hospital setting for sedation with a paucity of evidence as to the optimal agent
• Our previous research showed midazolam had few adverse events (AEs) in the prehospital setting
• However, longer term sequelae during the in-hospital period has not yet been described

Objective

• To determine the efficacy and incidence of AEs following midazolam administration during the first hour of Emergency Department (ED) stay

Methods

• A retrospective chart review from 2 urban centers over a four-year study period (January 2012 – December 2015)
• All cases of combative patients were examined (Figure 1)

Results

• Between January 2012 and December 2015 there were 269 EMS calls wherein the patient was documented as combative, of these 186 (69.1%) received midazolam
• During the first hour of stay, 68 (36.5%) required further sedation and 118 (63.4%) did not (Figure 2)
• A wide range of ED sedation medications were used in this first hour including: diazepam, midazolam, lorazepam, ketamine, propofol, etomidate, haloperidol, olanzepine, quetiapine, loxapine, risperidol, and trazadone
• There was 1 death and 1 AE in the ED
  *However, were deemed to be likely resulting from the underlying pathology (blunt traumatic cardiac arrest) and not due to prehospital midazolam administration
• Average ED length of stay (LOS) was 7.6 hours for all patients
• A total of 82 (44.1%) of patients were admitted to hospital following pre-hospital midazolam
  • Admission services included: Medical (31), Psychiatry (28), Intensive care (19), Surgical (3)
  • Mean in-hospital LOS was 13.1 days

Conclusions

• Pre-hospital use of midazolam for combative patients appears to be safe, with no reported AEs during the first 1 hour of their ED visit
• However, 36.5% of patients required further sedation within the first 1 hour of their ED arrival, signifying a potential incomplete management of the combative patient and compromising healthcare staff and patient safety
• Further research is required to determine the optimal sedation medication for pre-hospital combative patients

Figure 1. Derivation of the study population. EMS = Emergency Medical Services.
Admitting Services

Series 1

<table>
<thead>
<tr>
<th>Service</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
<td>31</td>
</tr>
<tr>
<td>Surgical</td>
<td>3</td>
</tr>
<tr>
<td>Psychiatry</td>
<td>28</td>
</tr>
<tr>
<td>Intensive Care</td>
<td>19</td>
</tr>
</tbody>
</table>